Viatris Inc. · NASDAQ:VTRS
Viatris — Mylan — Merger or Acquisition (May 2020)
8 slides from Viatris's merger presentation, May 11, 2020
Slide 1: VIATRIS: A New Champion for Global Health
May 11, 2020 VIATRIS: A New Champion for Global Health TM
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains “forward-looking statements”. Such forward-looking statements may include, without limitation, statements about the proposed combination of Upjohn Inc. (“Newco”) and Mylan N.V. (“Mylan”), which will immediately follow the proposed separation of
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale
Slide 4: Non-GAAP Financial Measures
Non-GAAP Financial Measures Mylan is not providing forward looking guidance for accounting principles generally accepted in the United States (“U.S. GAAP”) reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S.
Slide 5: Empowering people worldwide to live healthier, at every stage of life
Empowering people worldwide to live healthier, at every stage of life. PARTNERSHIP LEADERSHIP ACCESS
Slide 6: Substantial Merits of Mylan's Combination with Pfizer's Upjohn Business
Substantial Merits of Mylan’s Combination with Pfizer’s Upjohn Business Enhance our global scale and geographic reach. Accelerate Mylan’s own standalone business plan by at least 3-5 years. A few of the benefits we believe VIATRIS will deliver: Create an even stronger financial profile by Further st
Slide 7: Clear Roadmap of Execution to Optimize Total Shareholder Return (TSR)
Clear Roadmap of Execution to Optimize Total Shareholder Return (TSR) Years 0 1 2 3 4 5 6 7+ Business Execution Capital Allocation Operations Leverage New Pipeline Launches Capital Return Synergies Business Development New Pipeline Investment INTEGRATION PRODUCT LAUNCHES ~$3bn COST SYNERGIES REVENUE
Slide 8: Expected Attractive Financial Profile
Expected Attractive Financial Profile Selected Spec Pharma / Generics VIATRIS Avg. Est. Gross Debt / 2020E EBITDA3 * Pays Dividend / Dividend Yield4 2020E EBITDA Margin2 * ~4x 30% 28% 28% 18% 23% 24% Market Cap ($bn) ≤ 2.5x Sustained leverage target ~40%5 * Non-GAAP measures. Please see slide 4. Sou